The Next GLP-1s: Dual Fatty-Acid Conjugates and Combo Therapies Push Past Semaglutide

Two papers published this year sketch the next chapter. The first introduces TE-8105, a re-engineered GLP-1 built on what its developers call a 2FA-platform — a multi-arm linker that bolts two fatty acids onto the peptide with precise control over spacing and chemistry. The second tests an unlikely stack — GABA plus a GLP-1 receptor agonist — in a rat model of Wolfram syndrome, a rare disease that destroys pancreatic beta cells. Different problems, different molecules, same underlying signal: the future of this class is combinatorial and structural, not just bigger doses of what we already have.

Before we go further, the necessary caveat. Everything below is preclinical. Mice are not men, rats are not humans, and the graveyard of metabolic drugs that crushed it in rodents and flopped in trials is deep. Treat this as a map of where the field is pointing, not a shopping list.

Here's the part most coverage skips. Semaglutide isn't just GLP-1 in a syringe — it's GLP-1 with a fatty acid chain attached that lets it cling to albumin, the abundant carrier protein in your blood. That sticky relationship is what stretches its half-life from minutes to roughly a week. Once-weekly dosing is a fatty-acid story.

So the obvious engineering question: what if you used two fatty acids instead of one, and got the geometry right? That's the bet behind TE-8105, described this year in the Journal of Medicinal Chemistry. The team built a multi-arm linker that lets them tune the spacing, chain length, and attachment point of two fatty acids on a modified GLP-1 backbone, then screened the resulting library for albumin affinity and pharmacodynamics. TE-8105 came out on top.

In head-to-head animal work, TE-8105 outperformed semaglutide on the metrics that matter to anyone tracking this class. In diabetic mice, it delivered improved long-term glycemic control, more weight loss, and better liver health. In obese mice, it produced dose-dependent weight loss with favorable body composition changes — important language, because not all weight loss is created equal, and the lean-mass question is the one the lifting community keeps asking about this whole class.

The most distinctive finding may be the liver one. In a mouse model of nonalcoholic steatohepatitis — NASH, the aggressive fatty liver disease that's quietly become one of the biggest unmet needs in metabolic medicine — low-dose TE-8105 reduced liver steatosis and improved liver health. Semaglutide has shown liver-fat effects too, but a low-dose advantage is worth flagging.

While one team is rebuilding the molecule, another is rebuilding the protocol. A separate 2025 paper in Diabetology & Metabolic Syndrome tested GABA — yes, the same inhibitory neurotransmitter that turns up in sleep-stack supplements — alongside liraglutide, a first-generation GLP-1 agonist, in a rat model of Wolfram syndrome.

Wolfram syndrome is rare and brutal: a mutation in the WFS1 gene drives diabetes and neurodegeneration with no approved treatment. It's also a useful stress test for any drug claiming to protect beta cells, because in this model the cells are under genuine, genetically programmed attack.

The results were split in a telling way. GABA alone did nothing for the diabetic phenotype — a real divergence from conventional diabetes models, where GABA has shown islet-protective signals. Liraglutide alone delayed disease progression, consistent with what GLP-1 agonists have shown in other beta-cell-stress contexts. But the combination went further, modifying the cytoarchitecture of the Langerhans islets themselves — the actual cellular structure of the pancreas — in ways neither agent achieved alone.

Step back from the specific molecules and look at the pattern. Both papers are early — preclinical, animal models, small. Neither should change what anyone does this week. But they share a thesis that's worth internalizing if you follow this space: the second generation of GLP-1 therapy won't just be stronger appetite suppression. It'll be smarter pharmacokinetics, deliberate organ-level effects, and rational combinations that protect the very cells the disease is destroying.

For the evidence-first lifter watching this class with interest, that's a more useful frame than the breathless headlines. The interesting question isn't "how much weight can the next molecule make people lose." It's whether the next molecule preserves lean mass better, protects the liver at lower doses, and — when stacked with the right partner — actually rebuilds metabolic tissue rather than just suppressing appetite into it.

None of that is settled. All of it is testable. And both of these papers, for all their early-stage caveats, point at a class that's still very much accelerating.